N4 Pharma (N4P) Competitors GBX 0.46 -0.02 (-4.21%) As of 05/21/2025 11:03 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock N4P vs. RGT, CEL, HELD, HLN, BXP, HIK, HCM, INDV, AMYT, and APHShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), and Alliance Pharma (APH). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Argent BioPharma Celadon Pharmaceuticals Hellenic Dynamics Haleon Beximco Pharmaceuticals Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Alliance Pharma Argent BioPharma (LON:RGT) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Which has preferable valuation and earnings, RGT or N4P? N4 Pharma has higher revenue and earnings than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArgent BioPharmaN/AN/A-£17.53M-£0.24N/AN4 Pharma£8.84K221.63-£1.63M-£0.35-1.31 Does the media favor RGT or N4P? In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score. Company Overall Sentiment Argent BioPharma Neutral N4 Pharma Neutral Does the MarketBeat Community prefer RGT or N4P? N4 Pharma received 103 more outperform votes than Argent BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformArgent BioPharmaN/AN/AN4 PharmaOutperform Votes10365.61% Underperform Votes5434.39% Is RGT or N4P more profitable? Argent BioPharma has a net margin of -1,960.39% compared to N4 Pharma's net margin of -18,399.86%. Argent BioPharma's return on equity of 420.08% beat N4 Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Argent BioPharma-1,960.39% 420.08% -108.57% N4 Pharma -18,399.86%-90.68%-56.00% Which has more risk and volatility, RGT or N4P? Argent BioPharma has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500. Do insiders and institutionals hold more shares of RGT or N4P? 1.1% of Argent BioPharma shares are held by institutional investors. 17.8% of Argent BioPharma shares are held by insiders. Comparatively, 18.0% of N4 Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryArgent BioPharma beats N4 Pharma on 6 of the 11 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£1.96M£2.17B£5.37B£2.68BDividend Yield3.12%2.92%5.22%5.05%P/E Ratio-1.313.9826.84134.32Price / Sales221.63529.96392.34203,702.45Price / Cash2.2510.2538.2528.02Price / Book1.026.926.793.79Net Income-£1.63M£20.70B£3.23B£5.89B7 Day Performance-9.00%-0.40%1.53%0.65%1 Month Performance26.39%4.82%10.05%22.12%1 Year Performance-43.13%89.72%16.71%119.61% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.46-4.2%N/A-42.4%£1.96M£8,841.37-1.315Gap DownRGTArgent BioPharmaN/AN/AN/AN/A£8.31MN/A-0.65N/AGap DownHigh Trading VolumeCELCeladon PharmaceuticalsN/AGBX 5+11.1%N/A-95.0%£3.07M£123,381.65-0.632,780Gap DownHELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A-0.27N/AHLNHaleon2.0815 of 5 starsGBX 406.80+1.9%GBX 457+12.3%+24.8%£36.72B£11.07B34.2125,408News CoverageInsider TradeBXPBeximco PharmaceuticalsN/AGBX 34.75-3.5%N/A-12.5%£23.69B£7.08T3.735,500Gap UpHigh Trading VolumeHIKHikma Pharmaceuticals3.6746 of 5 starsGBX 2,004-1.0%GBX 2,655+32.5%+7.6%£5.56B£3.74B19.669,100HCMHUTCHMEDN/AGBX 221.35+0.2%N/A-32.4%£2.40B£771.01M-56.491,760News CoverageINDVIndivior1.6846 of 5 starsGBX 840.38-0.1%GBX 1,650+96.3%-36.2%£1.31B£1.40B-696.791,000AMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma1.8565 of 5 starsGBX 64.50-0.2%GBX 6,250+9,589.9%N/A£349.23M£183.50M-10.4091,000 Related Companies and Tools Related Companies Argent BioPharma Alternatives Celadon Pharmaceuticals Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Beximco Pharmaceuticals Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Alliance Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
